Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Feb. 8, 2012 - PRLog -- GlobalData estimates that the global laryngeal cancer therapeutics market (the seven key markets of the US, the UK, Germany, Italy, France, Spain and Japan) was worth $128.1m in 2011 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.4% to reach $166.9m by 2019. The existing market is strong and is represented by three approved products – Erbitux, Taxotere and bleomycin, of which only Erbitux is patent protected. Currently, Erbitux is only approved in the US and the EU and not Japan. The growth during 2006-2011 is primarily attributed to the launch of Taxotere and Erbitux for the treatment of Squamous Cell Carcinoma of the Head and Neck (SCCHN). The slow growth rate during the forecast period is attributed to the generic erosion of Taxotere, which lost its patent in 2010 and the patent expiry of Erbitux in 2014 and 2017 in Europe and the US, respectively. The laryngeal cancer market is expected to decline from 2017-2019 in the US, whereas it is expected to decline from 2014-2019 in Europe.

GlobalData has found that the laryngeal cancer market has low unmet need. The currently available products have moderate efficacy, safety and compliance profiles. The market is well served by the current products and there is low potential for new entrants. The approved drug Erbitux has high efficacy and safety levels and is expected to capture a greater market share from generics. The laryngeal cancer market is currently dominated by generics and off-label chemotherapy drugs. However, these drugs have various adverse effects such as neutropenia, thrombocytopenia, anemia, leucopenia and infections. Therefore, the laryngeal cancer therapeutics market is expected to be a relatively less open market for new entrants until 2019, with few opportunities for value capture.

A weak therapeutic pipeline with all Phase III molecules being sponsored by academic institutions/universities lowers the probability that any of them will be launched in the forecast period. The laryngeal cancer pipeline consists of 17 molecules, of which four are in Phase III development. Of the 17 molecules, 14 are first-in-class with novel mechanisms of action over the currently marketed products. Most of these first-in-class molecules are in Phase II development and it is too early to consider them promising molecules in the laryngeal cancer therapeutics market. In the laryngeal cancer pipeline, monoclonal antibodies and tyrosine kinase inhibitors (TKI) are the dominant mechanisms of action. Some of the other important mechanisms of action in the pipeline includes Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR), HDAC (histone deacetylases) inhibitors, KSP (Kinesin spindle protein) inhibitors, mTOR (mammalian target of rapamycin) inhibitors, 26S Proteosome inhibitors and TLR8 (Toll-like receptor 8) agonists.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....


GlobalData, the industry analysis specialist, has released its new report, “Laryngeal Cancer Therapeutics –Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global laryngeal cancer therapeutics market. The report identifies the key trends shaping and driving the global laryngeal cancer therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global laryngeal cancer therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Lary...


Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.